CClinicalTrials.gg
RecruitingNCT06373939Updated Jul 3, 2024

Performance and Safety of the Pneumoscope Device in Adults and Children

An interventional study of Digital lung auscultation and Pulse oximetry measurement in Respiratory Diseases, Pneumonia and Asthma, sponsored by Pediatric Clinical Research Platform. Recruiting at 1 site in Switzerland. Open to participants aged 1 Year and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Pediatric Clinical Research Platform · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Study summary

Respiratory diseases are associated with high morbidity and mortality worldwide. Proper diagnosis and risk assessment of these conditions are essential for optimal management. Clinicians use three particularly useful tools to identify these conditions when assessing the patient's status: the stethoscope, the pulse oximeter, and the thermometer. The Pneumoscope is an all-in-one device including a digital stethoscope, a pulse oximeter, and a thermometer. This study aims to assess the performance and safety of the Pneumoscope in recording respiratory sounds, body temperature, non-invasive blood oxygen saturation levels and heart rate in children and adults.

Read the detailed description

Respiratory diseases affect over 500 million people globally, ranking third in causes of death. Chronic obstructive pulmonary diseases impact 251 million individuals due to air pollution and tobacco smoke. Asthma is the most prevalent chronic disease in children, while pneumonia is the leading cause of death in children under 5. Respiratory infections are prominent in pediatric outpatient clinics, especially in low- and middle-income countries. Accurate diagnosis and risk assessment are crucial for effective management. Clinicians utilize three key tools: the stethoscope for auscultation, detecting abnormal breathing sounds; the pulse oximeter, indicating oxygen deficiency in inflamed lungs; and the thermometer, primarily for fever-related infections like pneumonia. Auscultation, while quick and non-invasive, suffers from user-dependent subjective interpretation, as highlighted by studies reporting low correct response rates, especially among non-pulmonologists. Pulmonary auscultation's sensitivity and specificity are notably low, particularly in unilateral or focal changes. Pulse oximetry, utilizing harmless light wavelengths, measures oxygenated hemoglobin concentration, with a saturation below 92% indicating hypoxia, albeit with reduced accuracy below 90%. Thermometers measure body temperature, with rectal measurement considered the gold standard in children, although non-contact methods remain contentious

The use of the Pneumoscope, a digital medical device, could address the above challenge. The Pneumoscope is designed to enhance respiratory disease diagnosis and provide heart rate, respiratory rate, pulse oximetry, and body temperature data. This project aims to evaluate its performance against gold standards in lung sound processing, pulse oximetry, and body temperature measurement. Furthermore, the Pneumoscope is envisioned to integrate artificial intelligence (AI) for future applications. Data on breath sounds, oximetry, heart rate, and temperature from patients with respiratory diseases will inform AI algorithms for disease recognition and risk assessment. Ultimately, this technology could enable remote diagnosis and follow-up, particularly beneficial for patients in low- and middle-income countries or with limited mobility. However, the current study focuses solely on assessing the Pneumoscope's performance as a standard digital stethoscope with integrated temperature and oximetry sensors, aiming to establish agreement with established clinical tools for digital lung auscultation, pulse oximetry, heart rate, and body temperature measurement.

This is a single center, open, non-controlled investigation that will be conducted at the University Hospitals of Geneva, Switzerland. This will be a non-inferiority study between Pneumoscope and CE marked comparable medical devices in children and adults.

02

Conditions studied

  • Respiratory Diseases
  • Pneumonia
  • Asthma
  • Cyanotic Heart Disease

Keywords

  • Stethoscopes
  • Oxygen Saturation
  • Thermometers
  • Digital Health
  • Auscultation
03

In context

Respiratory Tract Diseases

617 studies on the registry are indexed under Respiratory Tract Diseases; 111 are open to participants now.

This study's planned enrollment of 225 is above the median of 80 across 381 interventional studies indexed under Respiratory Tract Diseases.

Browse Respiratory Tract Diseases studies →

Lead sponsor

Pediatric Clinical Research Platform is the lead sponsor of 13 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Patients will be recruited from the pediatric and adult clinical departments of the Geneva University Hospitals.

Inclusion criteria

Inclusion Criteria:

  • Age > 1 year old.
  • Healthy patients on the day of auscultation OR
  • Patients with lower respiratory tract diseases (e.g., bronchitis, pneumonia, etc.). OR
  • Patients with low (i.e., \<92%) pulse oximetry values (e.g., cyanotic heart defect such as tetralogy of Fallot, transposition of great vessels, etc.). AND / OR
  • Patients with fever >38.0°C.
  • And for all: Information and written consent of the patient or a legal representative.

Exclusion criteria

Exclusion Criteria:

  • Refusal of consent.
  • Clinical signs of severity: acute hypoxia, hypercapnia, acute respiratory failure, acute circulatory failure.
  • Immune disorder, primary ciliary dyskinesia, antecedent of neonatal bronchopulmonary dysplasia.
  • Contraindications and limitations of the MD as described in the instructions for use.
  • Contraindications to the class of medical devices being studied, e.g. known hypersensitivity or allergy to the device material.
  • Clinically significant concomitant disease states.
  • Inability to follow the study procedures, e.g. due to language problems, psychological disorders, dementia, etc.
  • Participation in another study with an investigational drug or other medical device within 30 days prior to and during the present study.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    Children (>1 year old) and adult patients

    Patients with various respiratory conditions, such as asthma or pneumonia, along with healthy individuals, will be targeted to assess the Pneumoscope's performance under clinical conditions. Additionally, patients with lower blood oxygen saturation levels, such as those with cyanotic heart defects like tetralogy of Fallot, will also be included

    Device: Digital lung auscultation · Device: Pulse oximetry measurement · Device: Non invasive body temperature measurement

Interventions

  • DeviceDigital lung auscultation

    Two 30-second recordings will be made using CE-marked Littmann® CORE digital stethoscopes and the Pneumoscope at two bilateral lung positions on the posterior chest wall, focusing on the lower lobes. Spectral comparison and audio quality indices will be assessed between the Pneumoscope and the Littmann® CORE digital stethoscope. Comparator: The Gold Standard Littmann® CORE picks up sounds, such as heart and lung sounds, from a patient's body. After amplification and filtering, the sounds are sent to the user through a binaural headset. The stethoscope chest piece is designed for use with adult, pediatric, and infant patients.

  • DevicePulse oximetry measurement

    Pulse oximetry and heart rate will be measured using the CE-marked Masimo Rad-G® and iHealth® Air oximeters, as well as the Pneumoscope's built-in oximeter. Agreement between the Pneumoscope's oximeter and the reference oximeters will be evaluated. Measurement will take 30 second on the right index finger. Comparators: 1. The Gold Standard Masimo Rad-G® sensor is indicated for the continuous noninvasive peripheral monitoring of arterial oxygen saturation (SpO2) and pulse rate. Its use consists in positioning the emitting window of the sensor attachment envelope on the top of the finger nail bed, while the detector is placed opposite the emitter on the other side of the same finger. 2. The Gold Standard iHealth® Air works by projecting two beams of light through a clip with a transmitter and a detector that is placed around a finger, nail side down and screen side up.

    Also known as: Oximeters

  • DeviceNon invasive body temperature measurement

    Comparison of body temperature measurements between the Pneumoscope's built-in thermometer and Gold Standard thermometers (Terumo® C205 and VisioFocus Pro 06480). Comparators: 1. The Gold Standard Terumo® C205 is an axillary thermometer. Its use consists in placing the probe in the armpit, then lowering the arm and holding the device firmly until the temperature is stabilised and the temperature is read and displayed on the thermometer screen. 2. The Gold Standard VisioFocus Pro 06480 is an infrared thermometer that detects the infrared radiation naturally emitted by the body and in particular from the human forehead. Its use consists in holding the thermometer close to the forehead but without direct contact with the skin. The temperature reading is then projected on the patient's forehead using a symbol system.

    Also known as: Thermometers

06

What researchers measure

Primary outcomes

  1. Evaluation of Pneumoscope's built-in sensors

    To be used in patients and certified by competent authorities the performance of Pneumoscope has to be at least equal as comparable devices on the market. Performances of digital audio quality, as well as pulse oximetry, heart rate and temperature measurements by the Pneumoscope will be compared to CE certified similar medical devices used as gold-standards tools. Hence, the primary objective is to evaluate whether the three built-in sensors into the Pneumoscope are equivalent to CE marked Gold Standards: 1. Spectral comparison and other audio quality indices of recordings with the Pneumoscope and a commercially available digital stethoscope (Littmann® CORE digital stethoscope). 2. Agreement between the Pneumoscope thermometer and reference thermometers (Terumo® C205 and VisioFocus Pro® 06480). 3. Agreement between the Pneumoscope pulse oximeter (for blood oxygen saturation and heart rate) and reference oximeters (Masimo Rad-G® and iHealth® Air).

    Time frame: During procedure, i.e. 20 minutes per patient for both out- and inpatients.

Secondary outcomes

  1. Collect audio records of lung sounds for AI models training and sensor calibration

    The collected anonymised audio records of lung sounds will be used in the future to develop and validate AI algorithms for various bronchopulmonary diseases in children (pneumonia, asthma, bronchiolitis), as well as SARS-CoV-2 infections in adults.

    Time frame: During procedure, i.e. 20 minutes per patient for both out- and inpatients.

  2. Pulse oximetry

    The collected pulse oximetry measures will be used to calibrate the oximeter sensor.

    Time frame: During procedure, i.e. 20 minutes per patient for both out- and inpatients.

  3. Body temperature

    The collected, non-invasive, body temperature measures will be used to calibrate the thermometer sensor.

    Time frame: During procedure, i.e. 20 minutes per patient for both out- and inpatients.

07

Study locations

1 of 1 sites recruiting
  • Geneva University Hospitals
    Geneva, 1205, Switzerland
    • Alain Gervaix, Prof · Contact · Alain.Gervaix@hcuge.ch · (0)22 372 45 55
    • Johan Siebert, MD · Contact · Johan.Siebert@hcuge.ch · (0)79 553 40 72
    • Johan N Siebert, MD · Principal investigator
    • Laurence Lacroix-Duccardonnoy, MD · Sub investigator
    • Isabelle Ruchonnet-Métrailler, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — * Data types: Deidentified participant data. The final database will be shared on a non-commercial repository following the FAIR data principles. * How to access data: contact the principal investigator Dr Johan N. Siebert at: Johan.Siebert@hcuge.ch * When available: beginning 6 months and ending 10 years following article(s) publication.

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06373939
Lead sponsor
Pediatric Clinical Research Platform
Collaborators
University Hospital, Geneva
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Apr 15, 2024
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jul 3, 2024

Study contacts

Johan N Siebert, MD
Contact
Johan.Siebert@hcuge.ch
(0)79 553 40 72 ext. +41
Alain Gervaix, Prof
Contact
Alain.Gervaix@hcuge.ch
(0)22 372 45 55 ext. +41
Alain Gervaix, Prof
study director · University Hospital, Geneva

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion